Virtual Colonoscopy Using Omnipaque as a Contrast Agent

CompletedOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

March 14, 2024

Study Completion Date

March 31, 2025

Conditions
Colorectal Cancer
Interventions
DRUG

Iohexol

Iohexol (Omnipaque; GE Healthcare, Milwaukee, WI) is a low-osmolar non-ionic iodinated contrast agent that is approved by the FDA for oral use. It is routinely used orally for CT scans of the abdomen and pelvis, and has been used experimentally in CTC. Iohexol is better tolerated by patients and has a better safety profile than hyperosmolar iodinated and barium based contrast agents.

Trial Locations (1)

10467

Montefiore Medical Center, The Bronx

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GE Healthcare

INDUSTRY

lead

Montefiore Medical Center

OTHER